STOCK TITAN

Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced that its Chairman and CEO, Thomas Meyer, will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 AM ET on the conference portal and the company's website under 'Events and Presentations' in the 'Investors & Media' section. Altamira focuses on RNA therapeutics, viral infection protection, and inner ear therapeutics, with several products in various stages of development, including AM-125 for vertigo and Keyzilen for tinnitus.

Positive
  • None.
Negative
  • None.

HAMILTON, BERMUDA / ACCESSWIRE / January 5, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its Chairman and CEO, Thomas Meyer, will present at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.

The presentation will be available on-demand through the H.C. Wainwright conference portal. Beginning at 7:00 AM Eastern Time (13:00 PM Central European Time) on Monday, January 10, 2022, the presentation will also be available on the Company's website at www.altamiratherapeutics.com under "Events and Presentations" in the "Investors & Media" section.

About Altamira Therapeutics

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or for the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol "CYTO".

Investor contact:

Stephen Kilmer
646.274.3580
sjk@altamiratherapeutics.com

SOURCE: Altamira Therapeutics



View source version on accesswire.com:
https://www.accesswire.com/681058/Altamira-Therapeutics-to-Participate-in-the-HC-Wainwright-BioConnect-Virtual-Conference

FAQ

When is Altamira Therapeutics presenting at the H.C. Wainwright BioConnect Conference?

Altamira Therapeutics will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022.

Where can I watch Altamira Therapeutics' presentation?

The presentation will be available on-demand through the H.C. Wainwright conference portal and on Altamira's website starting January 10 at 7:00 AM ET.

What is the focus of Altamira Therapeutics?

Altamira Therapeutics focuses on RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics.

What products is Altamira developing?

Altamira is developing AM-125 for vertigo, Keyzilen and Sonsuvi for tinnitus, and Bentrio for airborne virus and allergen protection.

What is the stock symbol for Altamira Therapeutics?

Altamira Therapeutics trades on NASDAQ under the symbol CYTO.

Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)

NASDAQ:CYTO

CYTO Rankings

CYTO Latest News

CYTO Stock Data

1.88M
3.78M
0.53%
0.13%
0.31%
Biotechnology
Healthcare
Link
United States of America
Hamilton